Candidemia outcomes not improved with statin use

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Medicine

Background:

• Candidemia, a bloodstream infection caused by Candida species, is a significant contributor to patient morbidity and mortality.
• Statins, known to affect yeast membrane synthesis, prompted an investigation into their potential influence on candidemia outcomes.

Purpose of the Study:

• To evaluate the clinical outcomes of patients experiencing candidemia, comparing those who received statin therapy with those who did not.
• To determine if statin use influences mortality, length of hospital stay, or the need for intensive care in candidemia patients.

Main Methods:

• A retrospective review was conducted on 124 episodes of candidemia occurring between 2003 and 2008.
• Patients were categorized based on statin use (n=14) versus no statin use (n=110).
• Clinical outcomes assessed included all-cause mortality, candidemia-attributable mortality, length of stay, and intensive care unit (ICU) requirements.

Main Results:

• Overall mortality for candidemia episodes was 46%, with only 2% attributed directly to the fungal infection.
• No statistically significant differences in mortality, length of stay, or ICU admission rates were observed between patients who received statins and those who did not.
• A trend towards increased isolation of non-Candida albicans species, particularly Candida glabrata and Candida parapsilosis, was noted in the latter two years of the study.

Conclusions:

• Statin administration during an episode of candidemia did not demonstrate a significant impact on patient mortality, hospital length of stay, or intensive care needs.
• The study suggests that statin use is not associated with altered clinical outcomes in patients with candidemia.
• Rising rates of non-Candida albicans candidemia warrant continued surveillance and may influence treatment strategies.